Daniel Mercer

Daniel Mercer is a health and drug policy writer focused on ketamine, controlled substances, harm reduction and emerging mental health treatments.

His work examines both the legitimate medical use of ketamine and the risks surrounding substances obtained outside regulated healthcare settings. He writes about ketamine terminology and formulations, UK drug law, dependence and long-term health effects, harm reduction, treatment-resistant depression, esketamine and developments in clinical research.

Daniel specialises in translating complex medical research, public-health guidance and regulatory information into material that non-specialist readers can understand. Articles attributed to him draw primarily on NHS guidance, UK government publications, NICE and MHRA information, professional medical organisations and peer-reviewed scientific literature.

A particular focus of his work is helping readers understand the difference between medically supervised ketamine treatment and unregulated products for which identity, concentration, purity and origin may be uncertain.

Daniel is not a doctor, pharmacist or prescriber. His work is intended for education and harm reduction and does not replace individual medical advice, diagnosis or treatment.